Skip to content
10-Q

Quarterly Report

TARSUS PHARMACEUTICALS, INC. TARS

0001819790-25-000078

← back to feed
Filed
May 1, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 24, 2025 42.01M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $71.98M
Long Term Debt Q1 2025 · Dec 31, 2024 $71.85M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $175.79M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $94.82M
Current Liabilities Q1 2025 · Mar 31, 2025 $86.31M
Current Liabilities Q1 2025 · Dec 31, 2024 $80.61M
Total Liabilities Q1 2025 · Mar 31, 2025 $158.29M
Total Liabilities Q1 2025 · Dec 31, 2024 $152.46M
Current Assets Q1 2025 · Mar 31, 2025 $480.77M
Current Assets Q1 2025 · Dec 31, 2024 $356.71M
Total Assets Q1 2025 · Mar 31, 2025 $500.75M
Total Assets Q1 2025 · Dec 31, 2024 $376.99M
Shares Diluted Q1 2025 · Mar 31, 2024 35.3M sh
Capex Q1 2025 · Mar 31, 2024 $174K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$37.79M
Stockholders Equity Q1 2025 · Mar 31, 2024 $275.21M
Stockholders Equity Q1 2025 · Dec 31, 2023 $196.99M
Eps Diluted Q1 2025 · Mar 31, 2024 −$1.01
Eps Basic Q1 2025 · Mar 31, 2024 −$1.01
Sga Expense Q1 2025 · Mar 31, 2024 $51.58M
Rd Expense Q1 2025 · Mar 31, 2024 $12.07M
Net Income Q1 2025 · Mar 31, 2024 −$35.73M
Operating Income Q1 2025 · Mar 31, 2024 −$37.68M
Revenue Q1 2025 · Mar 31, 2024 $27.61M